CEFTRIAXONE SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ceftriaxone sodium and what is the scope of freedom to operate?
Ceftriaxone sodium
is the generic ingredient in seven branded drugs marketed by Acs Dobfar, Agila Speclts, Apotex, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu Antibiotics, Samson Medcl, Sandoz, Sandoz Inc, Teva, B Braun, Baxter Hlthcare, Anda Repository, Hikma, Hoffmann La Roche, Roche, Astral, Cephazone Pharma, Deva Holding As, Epic Pharma Llc, Hikma Farmaceutica, Teva Pharms Usa, and Wockhardt Bio Ag, and is included in forty-two NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-five drug master file entries for ceftriaxone sodium. Seventeen suppliers are listed for this compound.
Summary for CEFTRIAXONE SODIUM
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 27 |
| NDAs: | 42 |
| Drug Master File Entries: | 25 |
| Finished Product Suppliers / Packagers: | 17 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 26 |
| Patent Applications: | 2 |
| What excipients (inactive ingredients) are in CEFTRIAXONE SODIUM? | CEFTRIAXONE SODIUM excipients list |
| DailyMed Link: | CEFTRIAXONE SODIUM at DailyMed |
Recent Clinical Trials for CEFTRIAXONE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The George Institute | PHASE3 |
| University of Duhok | N/A |
| Sichuan Provincial People's Hospital | PHASE4 |
Pharmacology for CEFTRIAXONE SODIUM
| Drug Class | Cephalosporin Antibacterial |
Medical Subject Heading (MeSH) Categories for CEFTRIAXONE SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for CEFTRIAXONE SODIUM
US Patents and Regulatory Information for CEFTRIAXONE SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065169-001 | May 9, 2005 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Epic Pharma Llc | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065305-004 | Jan 11, 2008 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aurobindo Pharma Ltd | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065505-004 | Jul 31, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lupin | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INJECTION | 065263-001 | Sep 12, 2006 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fresenius Kabi Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065245-004 | Feb 15, 2006 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch